37
Participants
Start Date
December 28, 2023
Primary Completion Date
May 20, 2025
Study Completion Date
July 18, 2025
BMF-219
BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.
Manassas Clinical Research Center, Manassas
Lucas Research, Inc., Morehead City
Oceanic Research Group, North Miami Beach
University Diabetes & Endocrine Consultants, Chattanooga
Alliance for Multispecialty Research, LLC., Norman
Velocity Clinical Research, Dallas
Diabetes & Glandular Disease Clinic, P.A., San Antonio
Consano Clinical Research, LLC, Shavano Park
Texas Diabetes & Endocrinology, Round Rock
Dr. T.G Elliott Inc. dba BC Diabetes, Vancouver
Centricity Research, Toronto
Lead Sponsor
Biomea Fusion Inc.
INDUSTRY